首页> 外文期刊>American Journal of Pharmacological Sciences >Post Market In-vitro Bioequivalence Study on Representative Brands of Ciprofloxacin Tablets (500 mg) Prescribed in Typhoid Disease
【24h】

Post Market In-vitro Bioequivalence Study on Representative Brands of Ciprofloxacin Tablets (500 mg) Prescribed in Typhoid Disease

机译:伤寒病处方的环丙沙星片(500毫克)的代表性品牌的上市后体外生物等效性研究

获取原文
           

摘要

Seven brands of ciprofloxacin (One multinational and six local) were evaluated in terms of their bioavailability and efficacy. Pharmaceutical Parameters like weight variation, hardness, disintegration, dissolution and content assay were determined. Antibacterial susceptibility assay was performed on standard Strain of Salmonella typhi (ATCC 14028). MIC and ZOI were assessed. The results of the study indicated that three local brands had content less than the stated claim of USP and one brand did not pass the disintegration and dissolution tests, so they cannot be used as therapeutic alternatives. Antibacterial assay showed less MIC value of the brands having greater drug content while drug with lesser amount had greater MIC value. Similarly, one local brand showed greater zone of inhibition (ZOI) as compared to multinational brand having more price than the local brand.
机译:对七个品牌的环丙沙星(一个跨国公司和六个本地公司)的生物利用度和功效进行了评估。确定了诸如重量变化,硬度,崩解,溶解和含量测定的药物参数。在标准伤寒沙门氏菌菌株(ATCC 14028)上进行了药敏试验。评估了MIC和ZOI。研究结果表明,三个本地品牌的含量低于USP声明的含量,并且一个品牌未通过崩解和溶出度测试,因此不能用作治疗替代品。抗菌检测表明,具有较高药物含量的品牌的MIC值较小,而具有较少药物含量的品牌的MIC值较高。同样,与价格高于本地品牌的跨国品牌相比,一个本地品牌的抑制区(ZOI)更大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号